Summit Therapeutics reports survival benefit for cancer drug in trial (SMMT:NASDAQ)
· seekingalpha.com
Summit says ivonescimab beat Imfinzi in late-stage biliary tract cancer. See trial survival data, safety findings and why U.S.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...